CN112480389B - Low-oxygen responsive injectable hydrogel and preparation method thereof - Google Patents
Low-oxygen responsive injectable hydrogel and preparation method thereof Download PDFInfo
- Publication number
- CN112480389B CN112480389B CN201910854490.4A CN201910854490A CN112480389B CN 112480389 B CN112480389 B CN 112480389B CN 201910854490 A CN201910854490 A CN 201910854490A CN 112480389 B CN112480389 B CN 112480389B
- Authority
- CN
- China
- Prior art keywords
- ethylenediamine
- reaction
- double bond
- nitro
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000017 hydrogel Substances 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 239000001301 oxygen Substances 0.000 title description 12
- 229910052760 oxygen Inorganic materials 0.000 title description 12
- 238000006243 chemical reaction Methods 0.000 claims abstract description 30
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims abstract description 26
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 21
- -1 2-(2-methyl-5-nitro-1H-imidazol-1-yl) ethyl Chemical group 0.000 claims abstract description 21
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 20
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 20
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims abstract description 20
- 206010021143 Hypoxia Diseases 0.000 claims abstract description 18
- 229920002635 polyurethane Polymers 0.000 claims abstract description 16
- 239000004814 polyurethane Substances 0.000 claims abstract description 16
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 15
- 125000004386 diacrylate group Chemical group 0.000 claims abstract description 15
- 230000007954 hypoxia Effects 0.000 claims abstract description 15
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 15
- 238000006845 Michael addition reaction Methods 0.000 claims abstract description 9
- 239000000499 gel Substances 0.000 claims abstract description 8
- 238000002156 mixing Methods 0.000 claims abstract description 8
- 125000003277 amino group Chemical group 0.000 claims abstract description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 30
- YZEUHQHUFTYLPH-UHFFFAOYSA-N 2-nitroimidazole Chemical group [O-][N+](=O)C1=NC=CN1 YZEUHQHUFTYLPH-UHFFFAOYSA-N 0.000 claims description 26
- 239000007864 aqueous solution Substances 0.000 claims description 21
- 239000000243 solution Substances 0.000 claims description 21
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 14
- 239000001257 hydrogen Substances 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- 238000003756 stirring Methods 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- MAWGIUDKGUTHLG-UHFFFAOYSA-N 2-(2-methyl-5-nitroimidazol-1-yl)ethyl prop-2-enoate Chemical compound CC1=NC=C([N+]([O-])=O)N1CCOC(=O)C=C MAWGIUDKGUTHLG-UHFFFAOYSA-N 0.000 claims 4
- 125000003396 thiol group Chemical class [H]S* 0.000 claims 4
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 claims 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims 1
- 230000004043 responsiveness Effects 0.000 abstract description 11
- 229920000671 polyethylene glycol diacrylate Polymers 0.000 abstract description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 229920000587 hyperbranched polymer Polymers 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000001146 hypoxic effect Effects 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- DEPDDPLQZYCHOH-UHFFFAOYSA-N 1h-imidazol-2-amine Chemical group NC1=NC=CN1 DEPDDPLQZYCHOH-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000003519 biomedical and dental material Substances 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000010365 information processing Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000005389 magnetism Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
- C08G65/33303—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing amino group
- C08G65/33306—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing amino group acyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
- C08G65/33396—Polymers modified by chemical after-treatment with organic compounds containing nitrogen having oxygen in addition to nitrogen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种低氧响应性可注射水凝胶及其制备方法。具体地说，是利用乙二胺上的氨基与2‑(2‑甲基‑5‑硝基‑1H‑咪唑‑1‑基)乙基丙烯酸酯和聚乙二醇二丙烯酸酯(PEGDA)上的双键进行迈克尔加成反应，得到甲硝唑封端的超支化的聚氨基酯(HB‑PBAE‑MNZ)。将HB‑PBAE‑MNZ与巯基化透明质酸(HS‑HA)共混，得到具有低氧响应性的可注射水凝胶。这种凝胶制备方法简单，反应条件温和，生物相容性好，且具有低氧响应性。
The invention discloses a hypoxia-responsive injectable hydrogel and a preparation method thereof. Specifically, utilize the amino group on ethylenediamine and 2-(2-methyl-5-nitro-1H-imidazol-1-yl) ethyl acrylate and polyethylene glycol diacrylate (PEGDA) on The double bond was subjected to a Michael addition reaction to obtain a metronidazole-terminated hyperbranched polyurethane (HB-PBAE-MNZ). Blending HB‑PBAE‑MNZ with thiolated hyaluronic acid (HS‑HA) resulted in hypoxia-responsive injectable hydrogels. The gel preparation method is simple, the reaction conditions are mild, the biocompatibility is good, and it has hypoxia responsiveness.
Description
Technical Field
The invention relates to a low-oxygen-responsiveness injectable hydrogel and a preparation method thereof, in particular to a method for constructing a gel system by utilizing the Michael addition reaction between unreacted double bonds on a hyperbranched polymer and sulfydryl on sulfydryl hyaluronic acid, and nitroimidazole is used as an end capping group to ensure that the hydrogel has low-oxygen responsiveness.
Background
The hydrogel means a crosslinked polymer having a three-dimensional network structure in which a main chain or a branch chain contains a large amount of hydrophilic groups and is swollen with water, which is not dissolved in water, and which contains a large amount of water while maintaining a certain shape. Under the stimulation of external physical and chemical factors such as temperature, light, electricity, magnetism, sound, force, pH value, chemical substances and the like, the self properties of some polymer hydrogels such as phase, volume, shape, optics, electric field, mechanics, surface area, reaction rate, identification performance and the like change accordingly, and do work outwards simultaneously, and the hydrogel with stimulation responsiveness to the external environment change is called intelligent hydrogel. The intelligent hydrogel integrates perception, driving and information processing into a whole, and forms a functional material which is similar to an organism and has intelligent properties. The hydrogel materials with the environmental stimulus response behavior characteristics have wide application prospects in the field of microenvironment sensing.
The nitroimidazole group has low oxygen responsiveness, can be reduced into the aminoimidazole group by a reducing agent under the low oxygen condition, and can utilize hydrophilic and hydrophobic change to regulate and control the drug release.
The synthesis of the hyperbranched polymer is difficult to control, the proportion, the temperature and the reaction time need to be controlled to achieve the expected hyperbranched structure, and the structure of the polyurethane is degradable and has good biocompatibility.
Hyaluronic acid is used as a natural macromolecule, has good biocompatibility and is often used as a biomedical material. The thiolated hyaluronic acid can react with double bonds linked with ester bonds at room temperature to form a gel network system.
Disclosure of Invention
The invention aims to overcome the defects of the prior art, and aims to construct a gel system by utilizing the Michael addition reaction of the sulfydryl of the sulfhydrylated hyaluronic acid and unreacted active double bonds in the hyperbranched polymer, and the hydrogel has low-oxygen responsiveness by taking nitroimidazole as an end capping group.
The purpose of the invention is realized by the following technical scheme.
The invention relates to a hypoxia-responsive injectable hydrogel and a preparation method thereof, which are carried out according to the following steps:
(1) uniformly mixing dimethyl sulfoxide (DMSO) solution of polyethylene glycol diacrylate (PEGDA) and dimethyl sulfoxide (DMSO) solution of Ethylenediamine (EDA), wherein the molar ratio of double bonds of the polyethylene glycol diacrylate to active hydrogen of the ethylenediamine is 1 (1.1-1.4), and reacting in an oil bath to enable the double bonds on the polyethylene glycol diacrylate (PEGDA) and amino groups on the Ethylenediamine (EDA) to perform Michael addition reaction to obtain hyperbranched polyamino ester (HB-PBAE);
(2) adding a dimethyl sulfoxide (DMSO) solution of 2- (2-methyl-5-nitro-1H-imidazole-1-yl) ethyl acrylate into the reaction solution in the step (1), wherein the molar ratio of the double bond of the 2- (2-methyl-5-nitro-1H-imidazole-1-yl) ethyl acrylate to the active hydrogen of the ethylenediamine in the step (1) is (0.2-0.8): (1.1-1.4), continuing the reaction in an oil bath to react the double bond on the 2- (2-methyl-5-nitro-1H-imidazole-1-yl) ethyl acrylate with the unreacted amino in the reaction solution in the step (1) to obtain the hyperbranched polyamino ester (HB-PBAE-MNZ) terminated by the nitroimidazole group;
after the reaction in the step (1) is finished, purifying is not carried out, and 2- (2-methyl-5-nitro-1H-imidazole-1-yl) ethyl acrylate is directly added for reaction, so that the molar ratio of the sum of double bonds on polyethylene glycol diacrylate (PEGDA) and 2- (2-methyl-5-nitro-1H-imidazole-1-yl) ethyl acrylate to active hydrogen on ethylenediamine is more than 1, preferably 1.5: 1.25;
(3) uniformly mixing the aqueous solution of the nitroimidazole group-terminated hyperbranched polyaminoester (HB-PBAE-MNZ) prepared in the step (2) with the aqueous solution of the thiolated hyaluronic acid (HA-SH), wherein the mass ratio of the nitroimidazole group-terminated hyperbranched polyaminoester to the thiolated hyaluronic acid is (10-20): 1, fully reacting to enable unreacted double bonds on the nitroimidazole group-terminated hyperbranched polyaminoester (HB-PBAE-MNZ) and sulfydryl on the sulfhydrylated hyaluronic acid (HA-SH) to generate Michael addition reaction to generate the three-dimensional network stereo polymer.
In the step (1), the polyethylene glycol diacrylate (PEGDA) and the Ethylenediamine (EDA) react for 5-7h in oil bath at the temperature of 70-90 ℃.
In the step (2), 2- (2-methyl-5-nitro-1H-imidazole-1-yl) ethyl acrylate and hyperbranched polyamino ester (HB-PBAE) continue to react for 3-5H in an oil bath at 70-90 ℃; the molar ratio of the double bond of the 2- (2-methyl-5-nitro-1H-imidazole-1-yl) ethyl acrylate to the active hydrogen of the ethylenediamine in the step (1) is (0.2-0.5): (1.1-1.4).
After the reaction in the step (2) is finished, the reaction solution is purified by more than 5 times of diethyl ether.
In the step (3), the mass percentage concentration of the aqueous solution of the nitroimidazole group-terminated hyperbranched polyaminoester (HB-PBAE-MNZ) is 20 wt%, the mass percentage concentration of the aqueous solution of the thiolated hyaluronic acid (HA-SH) is 1 wt%, and the two are blended according to the volume ratio of 1: 1; fully carrying out the reaction by vortex stirring; the gelling temperature is room temperature, and the gelling time is 3-4 min.
The invention has the beneficial effects that: the hydrogel prepared by the invention has the advantages of simple preparation method, mild reaction conditions, good biocompatibility and low-oxygen responsiveness, and can be applied to the medical fields of drug sustained release and the like.
Drawings
FIG. 1 is a diagram of HB-PBAE-MNZ prepared in the example of the invention1H-NMR spectrum;
FIG. 2 is a gel-forming picture of 20 wt% HB-PBAE-MNZ and 1 wt% HA-SH;
FIG. 3 is a graph showing the UV absorption spectrum of an aqueous solution of HB-PBAE-MNZ with a mass fraction of 0.2% after reduction for 4 hours under normoxic and hypoxic conditions with an equal volume of an aqueous solution of 0.1mg/ml sodium bisulfite;
FIG. 4 is an injectable schematic of hydrogel formed by 20 wt% HB-PBAE-MNZ and 1 wt% HA-SH;
FIG. 5 shows the preparation of 2- (2-methyl-5-nitro-1H-imidazol-1-yl) ethyl acrylate according to an example of the present invention1H-NMR spectrum.
Detailed Description
The following is a further description of the invention and is not intended to limit the scope of the invention.
Putting 4g of metronidazole into a round-bottom flask, adding magnetons, adding 70ml of dichloromethane, adding 3ml of triethylamine into the solution, and uniformly mixing. Adding 10ml of chloroform into a constant pressure dropping funnel, adding 4ml of acryloyl chloride into the constant pressure dropping funnel, uniformly mixing, dropwise adding into the solution after preparation, and starting dropwise adding after gently stirring by a dropper.
Preparing broken ice blocks in advance, putting the broken ice blocks into an aluminum basin, adding a proper amount of water, and carrying out an ice-water bath reaction. And (3) putting the reaction system into an ice water bath for reaction for 12 hours, and then reacting at room temperature for 12 hours.
After the reaction is finished, the round-bottom flask is taken out by wearing a cloth glove, the round-bottom flask is wiped dry by using clean toilet paper, and each bottle mouth is opened to suck out small magnetons by using a magnet. Pouring off ice water for reaction, filtering the reaction solution, carrying out rotary evaporation on the filtrate for concentration, adding 50ml of chloroform for dilution after the filtrate is concentrated to about 15ml, washing with ultrapure water for three times, adding anhydrous calcium chloride particles into an organic phase for overnight drying after liquid separation, and carrying out rotary evaporation on the filtrate after filtration to obtain a light yellow solid product, namely the 2- (2-methyl-5-nitro-1H-imidazol-1-yl) ethyl acrylate.
By using1H NMR pairThe chemical structure of the 2- (2-methyl-5-nitro-1H-imidazol-1-yl) ethyl acrylate prepared in the example of the present invention is characterized, and from FIG. 5, it is clear that an absorption peak at 8.2ppm of hydrogen atoms on imidazole groups, an absorption peak at 2.3ppm of methyl groups on imidazole groups, an absorption peak at 5.9-6.6ppm of double bonds, and an absorption peak at 3.8-4.3ppm of methylene groups are observed, and the structure of 2- (2-methyl-5-nitro-1H-imidazol-1-yl) ethyl acrylate is well characterized, thereby proving that the 2- (2-methyl-5-nitro-1H-imidazol-1-yl) ethyl acrylate is successfully synthesized.
The low-oxygen responsive injectable hydrogel and the preparation method thereof are illustrated by taking the active hydrogen on the ethylenediamine and the double bond on the PEGDA-700 as 1.25:1 as an example.
1.56ml of polyethylene glycol diacrylate (PEGDA, number average molecular weight 700) was added to 3.7ml of DMSO and stirred until dispersed uniformly. 0.067ml of ethylenediamine was added to 1ml of DMSO. The two solutions were mixed in a round bottom flask and reacted for 6h at 80 ℃ in an oil bath. 0.8g of 2- (2-methyl-5-nitro-1H-imidazol-1-yl) ethyl acrylate (active hydrogen on ethylenediamine: the double bond of 2- (2-methyl-5-nitro-1H-imidazol-1-yl) ethyl acrylate is 1.25:0.5) was dissolved in 2ml of DMSO, and added to the above reaction solution to continue the reaction for 4 hours to obtain a nitroimidazole group-terminated hyperbranched polyamino ester (HB-PBAE-MNZ). After cooling, the product is purified three times by using more than five times of diethyl ether. The product was collected and stored at-20 ℃.
Preparing HB-PBAE-MNZ into 20 wt% aqueous solution, preparing thiolated hyaluronic acid into 1 wt% aqueous solution, blending according to the volume ratio of 1:1, performing vortex stirring to fully react, and standing at room temperature for 3min to obtain the hydrogel.
By using1H NMR shows the chemical structure of the nitro imidazole group-terminated hyperbranched polyaminoester (HB-PBAE-MNZ) prepared by the embodiment of the invention, as can be seen from figure 1, a peak with chemical shift of about 8.0ppm is a peak corresponding to hydrogen on imidazole, and the existence of the nitro imidazole group in HB-PBAE-MNZ is proved; in addition, the hydrogen on the double bond had three peaks at chemical shifts of about 6.2ppm, 6.3ppm and 6.0ppm, demonstrating that there were still unreacted double bonds, and thusThe successful synthesis of HB-PBAE-MNZ was demonstrated.
As can be seen from FIG. 2, after a 20 wt% HB-PBAE-MNZ aqueous solution and a 1 wt% thiolated hyaluronic acid aqueous solution were blended in a volume ratio of 1:1 and left standing for 3min, the mixed solution therein after the tube was turned over did not flow, thereby demonstrating that the mixed aqueous solution of HB-PBAE-MNZ and thiolated hyaluronic acid formed a hydrogel.
The Hypoxia responsiveness of the hyperbranched polyaminoester (HB-PBAE-MNZ) terminated by the nitroimidazole group prepared by the embodiment of the invention is tested according to the reference (Hypoxia-reactive block copolymers as anti-cancer drugs for enhanced chemoradiotherapeutics of bulk solid tumors, Biomaterials,181(2018): 360-371). In FIG. 3, curves (1) and (2) are UV curves after an aqueous solution of HB-PBAE-MNZ with a mass fraction of 0.2% was reduced by an equal volume of an aqueous solution of 0.1mg/ml sodium bisulfite under normoxic and hypoxic conditions for 4h, respectively. As can be seen from FIG. 3, the absorption peak at 310nm representing the nitroimidazole group is still high under the normoxic condition; under the condition of low oxygen, the peak of the nitroimidazole is obviously reduced, so that the nitroimidazole is reduced by a reducing agent under the condition of low oxygen, namely, the nitroimidazole group-terminated hyperbranched polyamino ester (HB-PBAE-MNZ) prepared by the embodiment of the invention has low-oxygen responsiveness. The subsequent hydrogel obtained by the same method is subjected to a hypoxia responsiveness test, and a similar result is obtained, namely the hydrogel prepared by the embodiment of the invention has hypoxia responsiveness.
As can be seen from FIG. 4, the hydrogel prepared in the example of the present invention has injectability.
The preparation of the natural polymer-based injectable hydrogel can be realized by adjusting the process parameters according to the content of the invention, and the performance of the hydrogel is basically consistent with that of the embodiment of the invention.
The invention has been described in an illustrative manner, and it is to be understood that any simple variations, modifications or other equivalent changes which can be made by one skilled in the art without departing from the spirit of the invention fall within the scope of the invention.
Claims (8)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910854490.4A CN112480389B (en) | 2019-09-10 | 2019-09-10 | Low-oxygen responsive injectable hydrogel and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910854490.4A CN112480389B (en) | 2019-09-10 | 2019-09-10 | Low-oxygen responsive injectable hydrogel and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112480389A CN112480389A (en) | 2021-03-12 |
| CN112480389B true CN112480389B (en) | 2022-02-08 |
Family
ID=74920097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910854490.4A Expired - Fee Related CN112480389B (en) | 2019-09-10 | 2019-09-10 | Low-oxygen responsive injectable hydrogel and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112480389B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113842503A (en) * | 2021-09-08 | 2021-12-28 | 南通大学 | Hydrogel of poly beta amino ester loaded with active substance, preparation method and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011111067A2 (en) * | 2010-03-09 | 2011-09-15 | Council Of Scientific & Industrial Research | A biodegradable polymeric hydrogel composition |
| CN102604118A (en) * | 2012-02-10 | 2012-07-25 | 华南理工大学 | Polyethylene glycol dendritic polymers and preparation method thereof |
| CN105176080A (en) * | 2015-07-28 | 2015-12-23 | 南京微腾生物科技有限公司 | Injectable hydrogel with good biocompatibility, preparation method and applications |
| CN107987285A (en) * | 2016-10-26 | 2018-05-04 | 天津大学 | A kind of conduction injection aquagel and preparation method thereof |
-
2019
- 2019-09-10 CN CN201910854490.4A patent/CN112480389B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011111067A2 (en) * | 2010-03-09 | 2011-09-15 | Council Of Scientific & Industrial Research | A biodegradable polymeric hydrogel composition |
| CN102604118A (en) * | 2012-02-10 | 2012-07-25 | 华南理工大学 | Polyethylene glycol dendritic polymers and preparation method thereof |
| CN105176080A (en) * | 2015-07-28 | 2015-12-23 | 南京微腾生物科技有限公司 | Injectable hydrogel with good biocompatibility, preparation method and applications |
| CN107987285A (en) * | 2016-10-26 | 2018-05-04 | 天津大学 | A kind of conduction injection aquagel and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| "pH-敏感甲硝唑壳聚糖-聚乙烯吡咯烷酮水凝胶的研究";何文等;《中国药学杂志》;20040331;第39卷(第3期);199-202 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112480389A (en) | 2021-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pourjavadi et al. | Injectable chitosan/κ-carrageenan hydrogel designed with au nanoparticles: A conductive scaffold for tissue engineering demands | |
| Dutta et al. | Temperature, pH and redox responsive cellulose based hydrogels for protein delivery | |
| Kang et al. | Photocrosslinked methacrylated carboxymethyl chitin hydrogels with tunable degradation and mechanical behavior | |
| CN108676178B (en) | Preparation method of modified polysaccharide hydrogel and prepared modified polysaccharide hydrogel | |
| CN105111512B (en) | A kind of chemical crosslinking type dextran hydrogel and preparation method thereof | |
| Chen et al. | Preparation and evaluation of thermo-reversible copolymer hydrogels containing chitosan and hyaluronic acid as injectable cell carriers | |
| EP3191016A1 (en) | Functionalized zwitterionic and mixed charge polymers, related hydrogels, and methds for their use | |
| Zhang et al. | Synthesis and characterization of thermosensitive graft copolymer of N-isopropylacrylamide with biodegradable carboxymethylchitosan | |
| CN110845743B (en) | Polyamino acid-based self-healing hydrogel based on quadruple hydrogen bond and preparation method thereof | |
| Chen et al. | Preparation and study on the volume phase transition properties of novel carboxymethyl chitosan grafted polyampholyte superabsorbent polymers | |
| EP1493754A1 (en) | Polysaccharide containing phosphorylcholine group and process for producing the same | |
| BR112019011780B1 (en) | POLYMER COMPRISING CARBON FROM BIOLOGICAL MATERIAL, ITS OBTAINMENT PROCESS AND ITS USE | |
| CN112812201B (en) | Thiol-modified hyaluronic acid and preparation method and application thereof | |
| Kamoun et al. | Photopolymerized PVA-g-GMA hydrogels for biomedical applications: factors affecting hydrogel formation and bioevaluation tests | |
| CN110522953A (en) | A kind of bionic joint lubricant and preparation method thereof | |
| CN108066819A (en) | A kind of natural polymer hydrogel film of high intensity and preparation method thereof | |
| Vasantha et al. | Halophilic polysulfabetaines–synthesis and study of gelation and thermoresponsive behavior | |
| CN112812200B (en) | Thiol-modified macromolecule compound and preparation method and application thereof | |
| Mrlik et al. | Mussel-mimicking sulfobetaine-based copolymer with metal tunable gelation, self-healing and antibacterial capability | |
| CN105694030B (en) | A hybrid antibacterial hydrogel composed of oligomeric amino acids and sodium alginate | |
| CN105175752A (en) | Multi-responsive pNIPAAm (poly(N-isopropylacrylamide))/(mPEG-g-CMCS) (methoxy polyethylene glycol-g-carboxymethyl chitosan) aquagel | |
| CN114042034A (en) | A kind of injectable thermosensitive drug sustained-release carrier hydrogel and preparation method thereof | |
| Enoch et al. | Thixotropic chitosan hydrogels for biomedical applications: Unravelling the effect of chitosan concentration on the mechanical behaviour | |
| CN112480417A (en) | Natural polymer-based injectable hydrogel and preparation method thereof | |
| CN112480389B (en) | Low-oxygen responsive injectable hydrogel and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20220208 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |